SK2292004A3 - Carbonyl benzoxazine compounds for enhancement of glutamatergic synaptic responses - Google Patents
Carbonyl benzoxazine compounds for enhancement of glutamatergic synaptic responses Download PDFInfo
- Publication number
- SK2292004A3 SK2292004A3 SK229-2004A SK2292004A SK2292004A3 SK 2292004 A3 SK2292004 A3 SK 2292004A3 SK 2292004 A SK2292004 A SK 2292004A SK 2292004 A3 SK2292004 A3 SK 2292004A3
- Authority
- SK
- Slovakia
- Prior art keywords
- substituted
- alkyl
- cycloalkyl
- hydrogen
- compound according
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/20—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
- C07D265/22—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33333401P | 2001-11-26 | 2001-11-26 | |
| PCT/US2002/037646 WO2003045315A2 (en) | 2001-11-26 | 2002-11-25 | Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK2292004A3 true SK2292004A3 (en) | 2004-09-08 |
Family
ID=23302344
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK229-2004A SK2292004A3 (en) | 2001-11-26 | 2002-11-25 | Carbonyl benzoxazine compounds for enhancement of glutamatergic synaptic responses |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7799913B2 (pl) |
| EP (1) | EP1448537A4 (pl) |
| JP (1) | JP4620349B2 (pl) |
| KR (1) | KR100915176B1 (pl) |
| CN (1) | CN1620440A (pl) |
| AU (1) | AU2002352886B2 (pl) |
| BR (1) | BR0214425A (pl) |
| CA (1) | CA2463592A1 (pl) |
| CZ (1) | CZ2004632A3 (pl) |
| EA (1) | EA011034B1 (pl) |
| GE (1) | GEP20063859B (pl) |
| HR (1) | HRP20040424A2 (pl) |
| HU (1) | HUP0402279A3 (pl) |
| IL (1) | IL161452A0 (pl) |
| MA (1) | MA26233A1 (pl) |
| MX (1) | MXPA04004815A (pl) |
| NO (1) | NO20041590L (pl) |
| NZ (1) | NZ532368A (pl) |
| PL (1) | PL371722A1 (pl) |
| SK (1) | SK2292004A3 (pl) |
| UA (1) | UA79940C2 (pl) |
| WO (1) | WO2003045315A2 (pl) |
| ZA (1) | ZA200403729B (pl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007342364A1 (en) * | 2007-01-03 | 2008-07-17 | Cortex Pharmaceuticals, Inc. | 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses |
| MY154877A (en) * | 2007-01-03 | 2015-08-14 | Servier Lab | 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamateric synaptic responses |
| US20130058915A1 (en) | 2010-03-02 | 2013-03-07 | Children's Medica Center Corporation | Methods and compositions for treatment of angelman syndrome and autism spectrum disorders |
| WO2012170845A2 (en) * | 2011-06-08 | 2012-12-13 | Heffernan Michele L R | Metabotropic glutamate receptor 5 modulators and methods of use thereof |
| BR112015031249A2 (pt) | 2013-06-13 | 2017-07-25 | Veroscience Llc | método de tratamento, método para tratar um distúrbio metabólico ou um elemento chave do mesmo, método para normalizar um ritmo diário de liberação de dopamina no sumn, método para estimular a liberação de dopamina de neurônios dopaminérgicos no sumn de um indivíduo e composição farmacêutica |
| KR20180019234A (ko) | 2015-06-26 | 2018-02-23 | 다케다 야쿠힌 고교 가부시키가이샤 | 콜린성 무스카린 m1 수용체의 조절제로서의 2,3-디히드로-4h-1,3-벤족사진-4-온 유도체 |
| JP6787913B2 (ja) | 2015-10-20 | 2020-11-18 | 武田薬品工業株式会社 | 複素環化合物 |
| US20190112300A1 (en) | 2016-03-29 | 2019-04-18 | Arnold Stan Lippa | Compositions And Methods For Treating Attention Deficit Disorders |
| JP7365332B2 (ja) | 2017-08-07 | 2023-10-19 | ジョイント・ストック・カンパニー “バイオキャド” | Ｃｄｋ８／１９阻害薬としての新規ヘテロ環式化合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2943087A (en) * | 1960-06-28 | n naoh | ||
| DE1122531B (de) * | 1957-09-13 | 1962-01-25 | Thomae Gmbh Dr K | Verfahren zur Herstellung von therapeutisch wertvollen 4-Oxo-2-(halogenalkyl)-2,3-dihydro-benzoxazinen-(1,3) |
| US4022139A (en) * | 1975-10-28 | 1977-05-10 | Blue Bell, Inc. | Tacker guide and method |
| EP0010348A1 (en) * | 1978-09-12 | 1980-04-30 | Imperial Chemical Industries Plc | Heterocyclic trichloromethyl derivatives, process for their preparation and their use |
| JPH0597824A (ja) * | 1990-09-25 | 1993-04-20 | Takeda Chem Ind Ltd | １，３−ベンゾオキサジン誘導体 |
| EP1156043B1 (en) | 1992-07-24 | 2003-11-12 | The Regents Of The University Of California | Drugs that enhance synaptic responses mediated by ampa receptors |
| US5650409A (en) | 1995-06-02 | 1997-07-22 | Cortex Pharmaceuticals, Inc. | Benzoyl piperidines/pyrrolidines for enhancing synaptic response |
| US5736543A (en) | 1996-04-03 | 1998-04-07 | The Regents Of The University Of California | Benzoxazines for enhancing synaptic response |
| GB9716962D0 (en) * | 1997-08-12 | 1997-10-15 | Univ Birmingham | Liver function test |
| WO1999016758A1 (en) * | 1997-10-27 | 1999-04-08 | Dr. Reddy's Research Foundation | Novel heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them |
| CA2320354A1 (en) * | 1998-02-18 | 1999-08-26 | Neurosearch A/S | Novel compounds and their use as positive ampa receptor modulators |
| US6124278A (en) | 1998-04-03 | 2000-09-26 | The Regents Of The University Of California | Acylbenzoxazines for enhancing synaptic response |
-
2002
- 2002-11-25 PL PL02371722A patent/PL371722A1/pl not_active Application Discontinuation
- 2002-11-25 AU AU2002352886A patent/AU2002352886B2/en not_active Ceased
- 2002-11-25 CA CA002463592A patent/CA2463592A1/en not_active Abandoned
- 2002-11-25 BR BR0214425-5A patent/BR0214425A/pt not_active Application Discontinuation
- 2002-11-25 NZ NZ532368A patent/NZ532368A/en not_active IP Right Cessation
- 2002-11-25 KR KR1020047007502A patent/KR100915176B1/ko not_active Expired - Fee Related
- 2002-11-25 US US10/495,049 patent/US7799913B2/en not_active Expired - Fee Related
- 2002-11-25 EA EA200400584A patent/EA011034B1/ru not_active IP Right Cessation
- 2002-11-25 HR HR20040424A patent/HRP20040424A2/xx not_active Application Discontinuation
- 2002-11-25 WO PCT/US2002/037646 patent/WO2003045315A2/en not_active Ceased
- 2002-11-25 UA UA20040503965A patent/UA79940C2/uk unknown
- 2002-11-25 CZ CZ2004632A patent/CZ2004632A3/cs unknown
- 2002-11-25 SK SK229-2004A patent/SK2292004A3/sk not_active Application Discontinuation
- 2002-11-25 IL IL16145202A patent/IL161452A0/xx unknown
- 2002-11-25 MX MXPA04004815A patent/MXPA04004815A/es active IP Right Grant
- 2002-11-25 JP JP2003546820A patent/JP4620349B2/ja not_active Expired - Fee Related
- 2002-11-25 GE GE5593A patent/GEP20063859B/en unknown
- 2002-11-25 EP EP02789846A patent/EP1448537A4/en not_active Withdrawn
- 2002-11-25 HU HU0402279A patent/HUP0402279A3/hu unknown
- 2002-11-25 CN CNA028234502A patent/CN1620440A/zh active Pending
-
2004
- 2004-04-19 NO NO20041590A patent/NO20041590L/no not_active Application Discontinuation
- 2004-05-14 ZA ZA200403729A patent/ZA200403729B/en unknown
- 2004-05-21 MA MA27691A patent/MA26233A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR0214425A (pt) | 2004-11-03 |
| HRP20040424A2 (en) | 2005-06-30 |
| ZA200403729B (en) | 2005-05-19 |
| IL161452A0 (en) | 2004-09-27 |
| CZ2004632A3 (cs) | 2004-08-18 |
| CN1620440A (zh) | 2005-05-25 |
| EP1448537A2 (en) | 2004-08-25 |
| EP1448537A4 (en) | 2005-05-04 |
| CA2463592A1 (en) | 2003-06-05 |
| UA79940C2 (en) | 2007-08-10 |
| EA011034B1 (ru) | 2008-12-30 |
| US7799913B2 (en) | 2010-09-21 |
| JP2005510532A (ja) | 2005-04-21 |
| MXPA04004815A (es) | 2005-02-17 |
| EA200400584A1 (ru) | 2005-02-24 |
| AU2002352886B2 (en) | 2008-10-16 |
| NZ532368A (en) | 2006-10-27 |
| NO20041590L (no) | 2004-07-12 |
| PL371722A1 (pl) | 2005-06-27 |
| HUP0402279A3 (en) | 2008-09-29 |
| MA26233A1 (fr) | 2004-07-01 |
| US20040259871A1 (en) | 2004-12-23 |
| WO2003045315A2 (en) | 2003-06-05 |
| JP4620349B2 (ja) | 2011-01-26 |
| HUP0402279A2 (hu) | 2005-02-28 |
| KR20040054777A (ko) | 2004-06-25 |
| GEP20063859B (en) | 2006-06-26 |
| AU2002352886A1 (en) | 2003-06-10 |
| WO2003045315A3 (en) | 2003-08-28 |
| KR100915176B1 (ko) | 2009-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU708212B2 (en) | Benzoxazines for enhancing synaptic response | |
| JP5139446B2 (ja) | グルタミン酸作動性シナプス応答を増強する３−置換−［１，２，３］−ベンゾトリアジノン化合物 | |
| WO1997036907A9 (en) | Benzoxazines for enhancing synaptic response | |
| AU737802B2 (en) | Benzofurazan compounds which enhance ampa receptor activity | |
| EP2114158B1 (en) | 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses | |
| JP4620349B2 (ja) | グルタメートシナプシス応答向上のためのカルボニルベンゾキサジン化合物 | |
| US6124278A (en) | Acylbenzoxazines for enhancing synaptic response | |
| KR101197754B1 (ko) | 글루타메이트성 시냅스 반응을 향상시키기 위한 ３치환된〔１，２，３〕벤조트리아지논 화합물 | |
| CN113651767A (zh) | 一种苯并异噁唑类杂环化合物及其制备方法和应用 | |
| HK1140105B (en) | 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses | |
| HK1163693A (en) | Bicyclic amide derivatives for enhancing glutamatergic synaptic responses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC9A | Refused patent application |